GlassScriptPhysician profile
Shelley Lanzkowsky
NPI 1992776942
$1,573.63
in general payments reported to CMS, 2019-2025
16 companies · $459 in 2025
The $459 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.75 · 2021: $165 · 2022: $222 · 2023: $340 · 2024: $371 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $680.24 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $330.89 | 2021-2024 | Jornay Pm |
| Tris Pharma INC | $171.94 | 2019-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $86.11 | 2022-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.72 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $47.02 | 2025 | Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $44.20 | 2023-2024 | Auvelity |
| Alkermes, INC. | $34.85 | 2025 | Aristada, Lybalvi |
| Avion Pharmaceuticals | $28.98 | 2023 | Methylphenidate Hydrochloride, Dhivy |
| Corium, LLC | $24.55 | 2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $14.68 | 2022 | |
| Collegium Pharmaceutical, INC. | $14.65 | 2025 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $14.35 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.06 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.39 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $2.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelley Lanzkowsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.